ArticleBioengineering & translational medicine2026
Cellular fragmentation underlies the immunogenicity of irreversible electroporation-mediated tumor cell killing.
Article in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A Three-Dimensional Hyaluronic Acid-Based Scaffold Model for Electroporation-Enhanced Resveratrol Therapy in Triple-Negative Breast Cancer.Cell biochemistry and biophysics · 2026Article
- Focal therapeutic conditions matter: How energy affects antigen presentation and T cell activation.Bioengineering & translational medicine · 2026Article
- Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.Cancers · 2026Review
- Measurement of metabolic activity by telemetric temperature sensing after immunotherapy and chemotherapy on three different mouse tumor models.BMC cancer · 2026Article
- Early career innovators shaping the future of bioengineering and translational medicine.Bioengineering & translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irreversible electroporation (IRE) is a focal ablative cancer therapy that destroys cells through membrane destabilization via pulsed electric fields. It also has the capacity to induce a systemic, anti-tumor immune response, thus acting as an in situ vaccine. Although many studies characterize the immunogenicity of focal therapies by their released biochemical constituents, here we show that the biophysical context of the presentation of these immunogenic signals is vital to understanding downstream immune functions. Compared to thermal ablation or cryoablation, IRE generates similar numbers of exosome-like particles (ELP, 50-200 nm) but significantly greater numbers of microparticles (MP, 200-1000 nm) and large debris particles (LDP, 2-6 μm) in both melanoma and pancreatic cancer cell lines. We show that LDPs contain antigen and tumor-associated DNA, which dendritic cells (DCs) internalize in greater proportions from IRE-treated cells compared to other treatments. For the submicron particles, we demonstrate both in vitro and in vivo that MPs induce greater T-cell proliferation and differentiation compared to ELPs on a per-particle basis. This novel biophysical analysis of the immunogenicity of IRE-treated cancer cells opens a new avenue toward improving the systemic immune response to focal ablation-based cancer immunotherapies via increasing cell fragmentation and particle generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.